Isatuximab

  • TRADE NAMES: ; Sarclisa (Sanofi-Aventis)
  • INDICATIONS: Indicated, in combination with pomalidomide and dexamethasone, for the treatment of adult patients with multiple myeloma
  • CLASS: Monoclonal antibody

FDA APPROVAL DATE: 03/02/2020

CLINICALLY IMPORTANT, POTENTIALLY HAZARDOUS INTERACTIONS WITH:

None known


The combination of isatuximab and pomalidomide is contraindicated in pregnant women.

Isatuximab is an IgG1-derived monoclonal antibody that binds to a specific extracellular epitope of CD38.

Our database has 16 adverse reactions for this drug across the following areas

Please login to see the rest of this drug profile


Not a subscriber? Click here to subscribe

GASTROINTESTINAL/HEPATIC.
GENITOURINARY.
HEMATOLOGIC.
LOCAL.
NEUROMUSCULAR/SKELETAL.
RESPIRATORY.


Page last updated 10/02/2020

Drug Eruption Mobile Site

Symbol key

Incidence info

  • <1%
  • 1-5%
  • 5-10%
  • 10-15%
  • 15-20%
  • 20-30%
  • >30%

Seriousness info

  • Hospitalization possible
  • Life threatening
  • Fatal

Warnings in other populations info

  • Breast feeding
  • Geriatric
  • Pediatric
^ Back to top